Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

After 10 Years Of Collaboration, AbbVie Discontinues Inventiva-Partnered Psoriasis Candidate

Published 31/10/2022, 11:50
© Reuters.  After 10 Years Of Collaboration, AbbVie Discontinues Inventiva-Partnered Psoriasis Candidate

  • Inventiva (NASDAQ: IVA) said that AbbVie Inc (NYSE: NYSE:ABBV) would stop developing cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for autoimmune diseases, following the analysis of a recently concluded nonclinical toxicology study.
  • Inventiva's cash runway, including the expected $12 million upfront payment from Sino Biopharm and the €25 million from the EIB credit facility, is not impacted by the discontinuation of the cedirogant clinical program and should allow funding as previously announced operations through Q4 2023.
  • Inventiva's R&D capabilities and objectives remain unaltered.
  • In 2012, Inventiva and AbbVie signed a multi-year drug discovery collaboration agreement to identify potent RORg inverse agonists for several autoimmune diseases.
  • In January, Inventia received a €4 million milestone payment from AbbVie for cedirogant (formerly ABBV-157) Phase 2b trial initiation in 2021 in adult patients with moderate to severe chronic plaque psoriasis.
  • According to IVA, the trial is expected to conclude in H1 2023.
  • Price Action: IVA shares are down 19.38% at $4.70 during the premarket session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.